enGene Therapeutics Inc. (S0N0)
XFRA 
NASDAQ (CM) Primary XFRA Summary
S0N0 Chart
EnGene Therapeutics: The Selloff Creates An Opportunity
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data for its sole asset, detalimogene voraplasmid. ENGN's therapy showed only a 25% 12-month complete response rate, underperforming competitors, but boasts a strong safety profile and Fast Track/RMAT status. Risks include FDA rejection and insurers declining coverage due to low efficacy, but current valuation implies limited further downside given the cash position.
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
enGene Therapeutics Inc. (S0N0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has enGene Therapeutics Inc. ever had a stock split?
enGene Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ronald H. W. Cooper CEO | XFRA Exchange | CA29286X1015 ISIN |
| CA Country | 81 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
enGene Holdings Inc. stands as a vanguard in the sector of biotechnological advancements, focusing its efforts through its subsidiary, enGene, Inc. This clinical-stage biotechnology company has dedicated itself to the development of genetic medicines, emphasizing the targeted delivery of therapeutics to mucosal tissues alongside other vital organs. Incorporated in 2023, enGene Holdings Inc. anchors its operations in Saint-Laurent, Canada, symbolizing a blend of innovative research and steadfast dedication towards addressing some of the most challenging medical conditions faced today.
Products and Services
EG-70 (detalimogene voraplasmid)
This product represents enGene Holdings Inc.'s forefront in its array of offerings, manifesting as a cutting-edge, non-viral immunotherapy. Targeted towards patients suffering from non-muscle invasive bladder cancer, particularly those with carcinoma-in-situ (Cis) who have not responded to the traditional Bacillus Calmette-Guérin treatment, EG-70 stands as a testament to the company's innovative strides in genetic medicine. This lead product candidate epitomizes the company's ambition to revolutionize the treatment landscape for a niche yet significantly impacted patient demographic.
